What Analysts Recommend for Bluebird Bio Stock
As previously discussed, analysts expect Bluebird Bio (BLUE) to post revenue of $9.6 million, a net adjusted loss of ~$123.5 million, and EPS of -$2.35 in the second quarter. Of the 21 analysts tracking Bluebird Bio, five recommend “strong buy,” nine recommend “buy,” six recommend “hold,” and one recommends “sell.”